Literature DB >> 18181201

Heparin-induced thrombocytopenia in myeloproliferative disorders: a rare or under-diagnosed complication?

Galia Spectre1, Yossi Kalish, Liliana Schliamser, David Varon.   

Abstract

Patients with myeloproliferative disorders (MPD) are prone to develop thrombotic complications and thus frequently receive heparin. Surprisingly heparin-induced thrombocytopenia (HIT) has been rarely reported in MPD and is potentially under-diagnosed due to the relatively high platelet count. We report three patients with MPD who developed HIT; all presented with a relative fall of platelet counts (although without an absolute thrombocytopenia), thrombosis or skin necrosis and a positive test for HIT antibodies (particle gel immunoassay). Risk factors for developing HIT in our patients were exposure to unfractionated heparin, a recent surgical procedure and female gender. We review the literature on HIT in MPD and discuss the diagnosis of HIT in the absence of an absolute thrombocytopenia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18181201     DOI: 10.1002/ajh.21128

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  8 in total

1.  Heparin-induced thrombocytopenia associated with polycythemia vera during the treatment of acute coronary syndrome.

Authors:  Takashi Yoshizane; Makoto Iwama; Takahiro Ueno; Maya Ishiguro; Yoshiaki Goto; Koji Ono; Masazumi Arai; Toshiyuki Noda
Journal:  J Cardiol Cases       Date:  2016-04-28

2.  Treatment and outcomes of heparin-induced thrombocytopenia (HIT) in patients with neoplasm, a case series.

Authors:  Chieh Min Benjamin Lai; Tyler Smith; Agnes Yuet Ying Lee
Journal:  J Thromb Thrombolysis       Date:  2021-02-13       Impact factor: 2.300

3.  Multicenter analysis of the use of transjugular intrahepatic portosystemic shunt for management of MPN-associated portal hypertension.

Authors:  Christopher R Reilly; Daria V Babushok; Karlyn Martin; Jerry L Spivak; Michael Streiff; Ranjeeta Bahirwani; Jeffrey Mondschein; Brady Stein; Alison Moliterno; Elizabeth O Hexner
Journal:  Am J Hematol       Date:  2017-07-26       Impact factor: 10.047

4.  Anti-Platelet Factor 4/Heparin Antibody Formation Occurs Endogenously and at Unexpected High Frequency in Polycythemia Vera.

Authors:  Sara C Meyer; Eva Steinmann; Thomas Lehmann; Patricia Muesser; Jakob R Passweg; Radek C Skoda; Dimitrios A Tsakiris
Journal:  Biomed Res Int       Date:  2017-06-18       Impact factor: 3.411

5.  Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms.

Authors:  Valerio De Stefano; Guido Finazzi; Tiziano Barbui
Journal:  Blood Cancer J       Date:  2018-06-26       Impact factor: 11.037

6.  High prevalence of heparin induced thrombocytopenia with thrombosis among patients with essential thrombocytemia carrying V617F mutation.

Authors:  Roberto Castelli; Paolo Gallipoli; Riccardo Schiavon; Thomas Teatini; Giorgio Lambertenghi Deliliers; Luigi Bergamaschini
Journal:  J Thromb Thrombolysis       Date:  2018-01       Impact factor: 2.300

7.  Heparin-Induced Thrombocytopenia in a Patient with Essential Thrombocythemia: A Case Based Update.

Authors:  Edva Noel; Naeem Abbas; Yevegeniy Skaradinskiy; Zwi Schreiber
Journal:  Case Rep Hematol       Date:  2015-10-22

8.  What cardiologists should know about essential thrombocythemia and acute myocardial infarction: report of two cases and advanced heart failure therapies considerations.

Authors:  Marie-Camille Soucy-Giguère; Pierre Yves Turgeon; Mario Sénéchal
Journal:  Int Med Case Rep J       Date:  2019-08-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.